(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Corbus Pharmaceuticals Holdings's earnings in 2026 is -$67,512,000.On average, 11 Wall Street analysts forecast CRBP's earnings for 2026 to be -$91,927,010, with the lowest CRBP earnings forecast at -$125,230,387, and the highest CRBP earnings forecast at -$51,421,622. On average, 11 Wall Street analysts forecast CRBP's earnings for 2027 to be -$98,047,754, with the lowest CRBP earnings forecast at -$156,021,925, and the highest CRBP earnings forecast at -$47,551,177.
In 2028, CRBP is forecast to generate -$113,206,557 in earnings, with the lowest earnings forecast at -$148,797,095 and the highest earnings forecast at -$66,719,094.